TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22111754

Group type: EXPERIMENTAL
Intervention: Tolvaptan
Number of subjects: 688336

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 688336
Study: 19543005

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 14

Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 14
Study: 17292948

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 2.5 mg bid
Number of subjects: 625

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 5 mg bid
Number of subjects: 625

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 10 mg bid
Number of subjects: 625

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 20 mg bid
Number of subjects: 625

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 30 mg bid
Number of subjects: 625

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 30 mg od
Number of subjects: 625

Group type: COMPARATOR
Intervention: Enoxaparin 40 mg od
Number of subjects: 625

Group type: EXPERIMENTAL
Intervention: Rivaroxaban (all doses)
Number of subjects: 625

Group type: COMPARATOR
Intervention: Enoxaparin
Number of subjects: 625
Study: 15355132

Group type: EXPERIMENTAL
Intervention: Model-based training
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Memory-based training
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both types of training
Number of subjects: 0
Study: 11231430

Group type: EXPERIMENTAL
Intervention: Dalteparin 60 IU/kg IV during PCI
Number of subjects: 59

Group type: COMPARATOR
Intervention: Dalteparin 40 IU/kg IV during PCI
Number of subjects: 59
Study: 9728784

Group type: EXPERIMENTAL
Intervention: Thromboprophylaxis with tinzaparin for four weeks (n = 58)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Control group with thromboprophylaxis for one week (n = 60)
Number of subjects: 118
Study: 8299092

Group type: EXPERIMENTAL
Intervention: Supportive care plus melatonin (20 mg/day at 8:00 p.m. orally)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Supportive care alone (steroids plus anticonvulsant agents)
Number of subjects: 50
Study: 3142634

Group type: EXPERIMENTAL
Intervention: Noxythiolin irrigation (2.5% solution)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 20
Study: 4533699

Group type: EXPERIMENTAL
Intervention: Prostaglandin F2alpha (PGF2alpha) with oxytocin
Number of subjects: 32

Group type: COMPARATOR
Intervention: Hypertonic saline (20%) with oxytocin
Number of subjects: 32
Study: 30578714

Group type: EXPERIMENTAL
Intervention: Treatment according to a protocol for precursor lymphoblastic lymphoma
Number of subjects: 11
Study: 28895220

Group type: EXPERIMENTAL
Intervention: Guiding Stars system (intervention supermarkets)
Number of subjects: 783

Group type: COMPARATOR
Intervention: Control supermarkets
Number of subjects: 783
Study: 25854692

Group type: EXPERIMENTAL
Intervention: Radial access and bivalirudin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Femoral access (control group)
Number of subjects: 0
Study: 23625531

Group type: EXPERIMENTAL
Intervention: DHA
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Multivitamins/minerals
Number of subjects: 173

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Both (DHA and multivitamins/minerals)
Number of subjects: 173
Study: 21853854

Group type: EXPERIMENTAL
Intervention: Intermittent GVS at 3.5 mA or 5 mA
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Continuous GVS at 3.5 mA or 5 mA
Number of subjects: 60
Study: 19860889

Group type: EXPERIMENTAL
Intervention: D-aspartate (DADAVIT) for 12 days in humans (23 men)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: D-aspartate (20 mM solution) for 12 days in rats (10 rats)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: D-aspartate in rat pituitary
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: D-aspartate in rat Leydig cells
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo in humans (20 men)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo in rats
Number of subjects: 33
Study: 16901286

Group type: EXPERIMENTAL
Intervention: Peginterferon alpha-2a (40 kDa) plus ribavirin for 24 weeks
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Peginterferon alpha-2a (40 kDa) plus ribavirin for 48 weeks
Number of subjects: 117
Study: 15641601

Group type: EXPERIMENTAL
Intervention: Sevoflurane at MAC 1
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Sevoflurane at MAC 1.5
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 80
Study: 10910868

Group type: EXPERIMENTAL
Intervention: Conventional intubation with propofol (median dose: 2.74 +/- 1.59 mg/kg; range 1.95-7.07 mg/kg)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Fiberoptic intubation with propofol (median dose: 1.37 +/- 0.59 mg/kg; range 0.72-2.86 mg/kg)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Both groups (conventional and fiberoptic)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 32
Study: 8632935

Group type: EXPERIMENTAL
Intervention: 5.5% energy as 60:40 whey:casein protein
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 6.7% energy as 60:40 whey:casein protein
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 8.0% energy as 60:40 whey:casein protein
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 4.7% protein for toddlers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 6.4% protein for toddlers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 8.0% protein for toddlers
Number of subjects: 0
Study: 1484577

Group type: EXPERIMENTAL
Intervention: EACA treatment before operation
Number of subjects: 757

Group type: COMPARATOR
Intervention: No EACA treatment
Number of subjects: 757
Study: 3933890

Group type: EXPERIMENTAL
Intervention: gamma‐L‐Glutamyl‐L‐dopa at 12.5 micrograms min‐1 kg‐1
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: gamma‐L‐Glutamyl‐L‐dopa at 100 micrograms min‐1 kg‐1
Number of subjects: 8
Study: 30268859

Group type: EXPERIMENTAL
Intervention: Limited screening plus FDG PET/CT scan
Number of subjects: 394

Group type: COMPARATOR
Intervention: Limited screening
Number of subjects: 394

Group type: EXPERIMENTAL
Intervention: Extensive screening
Number of subjects: 394
Study: 28314743

Group type: EXPERIMENTAL
Intervention: Flucloxacillin with clindamycin
Number of subjects: 410

Group type: COMPARATOR
Intervention: Flucloxacillin alone
Number of subjects: 410
Study: 25297900

Group type: EXPERIMENTAL
Intervention: Unifocal tumors
Number of subjects: 6134

Group type: EXPERIMENTAL
Intervention: Multifocal tumors
Number of subjects: 6134

Group type: EXPERIMENTAL
Intervention: Multicentric tumors
Number of subjects: 6134

Group type: EXPERIMENTAL
Intervention: Achieved pCR or breast conservation after NACT
Number of subjects: 6134
Study: 23177180

Group type: EXPERIMENTAL
Intervention: Efinaconazole 10% solution
Number of subjects: 1655

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 1655
Study: 20947098

Group type: EXPERIMENTAL
Intervention: Intravenous methylprednisolone treatment during relapse
Number of subjects: 0

Group type: COMPARATOR
Intervention: CSF concentrations of CXCL13
Number of subjects: 0

Group type: COMPARATOR
Intervention: Serum CCL20 levels
Number of subjects: 0

Group type: COMPARATOR
Intervention: CCL17 and CCL20 detection in CSF
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Serum CXCL13 and CCL20 levels
Number of subjects: 0
Study: 18641371

Group type: EXPERIMENTAL
Intervention: Cryo/Cuff
Number of subjects: 60

Group type: COMPARATOR
Intervention: KoldBlue
Number of subjects: 60
Study: 17186737

Group type: EXPERIMENTAL
Intervention: Qidi Yiqi Yangyin Huoxue Recipe (QYYHR)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Basal hypoglycemic treatment (Control)
Number of subjects: 100
Study: 14617116

Group type: EXPERIMENTAL
Intervention: Atropine and ketamine before propofol infusion
Number of subjects: 122

Group type: COMPARATOR
Intervention: Atropine, normal saline solution, and a mixture of propofol with lidocaine
Number of subjects: 122
Study: 10709427

Group type: EXPERIMENTAL
Intervention: Intranasal nafarelin acetate (NA) 800 micrograms/d
Number of subjects: 88

Group type: COMPARATOR
Intervention: Leuprolide acetate (LA) 0.5 mg/d
Number of subjects: 88
Study: 7554554

Group type: EXPERIMENTAL
Intervention: Corticosteroids (Cs)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group (RA patients not on Cs)
Number of subjects: 52
Study: 1682739

Group type: EXPERIMENTAL
Intervention: Erythropoietin treatment
Number of subjects: 15

Group type: COMPARATOR
Intervention: Concomitant treatment with 300 mg aspirin daily
Number of subjects: 15
Study: 7019929

Group type: EXPERIMENTAL
Intervention: 400 mg glucosamine sulphate (injectable)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Oral glucosamine capsules (6 x 250 mg daily)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (oral)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Piperazine/chlorbutanol combination (intravenous or intramuscular)
Number of subjects: 30
Study: 31677590

Group type: EXPERIMENTAL
Intervention: Hydroxyethyl starch 6% (130/0.4)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Albumin 5%
Number of subjects: 55
Study: 27799322

Group type: EXPERIMENTAL
Intervention: Head cooling for 72 hours starting within 6 hours of birth
Number of subjects: 194

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 194
Study: 26133971

Group type: EXPERIMENTAL
Intervention: Caffeine (6 mg/kg of body mass)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo (dextrose)
Number of subjects: 8
Study: 24694926

Group type: EXPERIMENTAL
Intervention: MDMA (1.5 mg/kg)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: MDMA (0.75 mg/kg)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Methamphetamine (20 mg)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: MDMA (0.75 mg/kg) and MDMA (1.5 mg/kg)
Number of subjects: 13
Study: 22710356

Group type: EXPERIMENTAL
Intervention: Beetroot (BR) beverage, 500 ml daily for 6 days
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo (PL), 500 ml daily for 6 days
Number of subjects: 14
Study: 19686592

Group type: EXPERIMENTAL
Intervention: TetraVisc 0.5% (0.5 ml)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Lidocaine 2% gel (1 ml)
Number of subjects: 122
Study: 17653981

Group type: EXPERIMENTAL
Intervention: High fructose corn syrup (HFCS) consumption
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Epidemiologic studies and randomized controlled trials
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HFCS and sucrose consumption
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High fructose corn syrup (HFCS)
Number of subjects: 0
Study: 15666940

Group type: EXPERIMENTAL
Intervention: Achievement Goal Priming
Number of subjects: 66

Group type: COMPARATOR
Intervention: Neutral Priming
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Conscious Monitoring (task presented as a measure of ability)
Number of subjects: 66
Study: 12226017

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate via HFA‐134a pMDI
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate via Diskhaler
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study: 9845649

Group type: EXPERIMENTAL
Intervention: Forced air warming blanket
Number of subjects: 100

Group type: COMPARATOR
Intervention: Circulating water mattress
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Hypothermia (temperature less than 36 degrees C)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Hypothermic aneurysm patients
Number of subjects: 100
Study: 10210927

Group type: EXPERIMENTAL
Intervention: Octreotide (500 micrograms two times a day subcutaneous for six months)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Octreotide
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control (supportive care)
Number of subjects: 6
Study: 1763797

Group type: EXPERIMENTAL
Intervention: High-dose intravenous quinine (20 mg salt/kg loading, then 10 mg salt/kg every 12 hr)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Intramuscular quinine (20 mg salt/kg loading, then 10 mg salt/kg every 12 hr)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Low-dose intravenous quinine (10 mg salt/kg loading, then 5 mg salt/kg every 12 hr)
Number of subjects: 59
Study: 7037043

Group type: EXPERIMENTAL
Intervention: 1 litre of 10% (w/v) glucose intravenously over 1 h
Number of subjects: 3

Group type: COMPARATOR
Intervention: 1 litre of 0.9% sodium chloride solution intravenously over 1 h
Number of subjects: 3

Group type: COMPARATOR
Intervention: No supplementary infusion
Number of subjects: 3
Study: 31649028

Group type: EXPERIMENTAL
Intervention: Bilateral ESP blocks with 20 mL 0.5% ropivacaine
Number of subjects: 54

Group type: COMPARATOR
Intervention: Intrathecal morphine (ITM) 400 µg
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Bilateral ESP blocks
Number of subjects: 54

Group type: COMPARATOR
Intervention: Intrathecal morphine (ITM)
Number of subjects: 54
Study: 28270292

Group type: COMPARATOR
Intervention: 70 kV group
Number of subjects: 82
Study: 25319074

Group type: EXPERIMENTAL
Intervention: Gefitinib
Number of subjects: 73

Group type: COMPARATOR
Intervention: VMP chemotherapy
Number of subjects: 73
Study: 24192073

Group type: EXPERIMENTAL
Intervention: Power brushing
Number of subjects: 175

Group type: COMPARATOR
Intervention: Manual brushing
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Power brushing and Manual brushing
Number of subjects: 175
Study: 21457539

Group type: COMPARATOR
Intervention: Anthelmintic treatment
Number of subjects: 0
Study: 18073313

Group type: EXPERIMENTAL
Intervention: L-arginine/GHRH
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: GHRH/GHRP-2
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: L-arginine/GHRP-2
Number of subjects: 22

Group type: COMPARATOR
Intervention: Integrated GH responses
Number of subjects: 22
Study: 17066505

Group type: EXPERIMENTAL
Intervention: Phentermine-HCl 37.5 mg once daily with behavioral therapy
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo once daily with behavioral therapy
Number of subjects: 68
Study: 12957347

Group type: EXPERIMENTAL
Intervention: Buprenorphine
Number of subjects: 405

Group type: COMPARATOR
Intervention: Methadone
Number of subjects: 405
Study: 10853298

Group type: EXPERIMENTAL
Intervention: FA-specific IgE antibody measurement
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Total IgE measurement
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: sECP measurement
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Lung function tests (FEV1%, %VC, V25/HT)
Number of subjects: 80
Study: 8704111

Group type: EXPERIMENTAL
Intervention: Low sodium diet (20 mmol NaCl/day)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: High sodium diet (320 mmol NaCl/day)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Switch from high to low sodium intake
Number of subjects: 61

Group type: COMPARATOR
Intervention: Baseline active kallikrein excretion
Number of subjects: 61
Study: 1793331

Group type: EXPERIMENTAL
Intervention: Perindopril (2 or 4 mg)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125
Study: 6133000

Group type: EXPERIMENTAL
Intervention: 2 g SASP daily
Number of subjects: 391

Group type: EXPERIMENTAL
Intervention: 1, 2, or 4 g SASP daily for 6 months
Number of subjects: 391

Group type: COMPARATOR
Intervention: 20 mg prednisolone daily for one week
Number of subjects: 391

Group type: COMPARATOR
Intervention: Dummy tablets for one week
Number of subjects: 391
Study: 30888989

Group type: EXPERIMENTAL
Intervention: 123I‐6DIG
Number of subjects: 11
Study: 30176051

Group type: EXPERIMENTAL
Intervention: Nulliparous women
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Parous women
Number of subjects: 206
Study: 26837684

Group type: EXPERIMENTAL
Intervention: BDD-NET (n=47)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Supportive therapy (n=47)
Number of subjects: 94
Study: 25139539

Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 22464259

Group type: EXPERIMENTAL
Intervention: Dexlansoprazole 60 mg
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg
Number of subjects: 160

Group type: COMPARATOR
Intervention: Omeprazole 80 mg
Number of subjects: 160
Study: 20387351

Group type: EXPERIMENTAL
Intervention: Aceclofenac
Number of subjects: 423

Group type: EXPERIMENTAL
Intervention: Nabumetone
Number of subjects: 423

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 423
Study: 17621520

Group type: EXPERIMENTAL
Intervention: Potassium bromide (started at 45 mg/kg, raised to 70 mg/kg)
Number of subjects: 113
Study: 15981008

Group type: EXPERIMENTAL
Intervention: Nadroparin (0.3 ml, 7,500 anti-Xa units)
Number of subjects: 2474

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2474

Group type: EXPERIMENTAL
Intervention: Nadroparin
Number of subjects: 2474
Study: 12560610

Group type: EXPERIMENTAL
Intervention: Treatment strategy according to American College of Cardiology / American Heart Association practice guidelines (2002)
Number of subjects: 0
Study: 9808394

Group type: EXPERIMENTAL
Intervention: Liquid elemental peptide diet for four weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Continuation of usual food (control group)
Number of subjects: 30
Study: 8742865

Group type: EXPERIMENTAL
Intervention: Creatine supplementation (4 x 70 mg.kg‐1 body mass per day mixed with 5 g glucose)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo (4 x 10 g glucose per day)
Number of subjects: 17
Study: 2506503

Group type: EXPERIMENTAL
Intervention: Intravenous nitroglycerin (NTG) at 0.25 micrograms/kg/min
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Intravenous nitroglycerin (NTG) at 0.50 micrograms/kg/min
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Intravenous nitroglycerin (NTG) at 1.00 micrograms/kg/min
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Intravenous nitroglycerin (NTG) at 2.00 micrograms/kg/min
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 10
Study: 1112210

Group type: EXPERIMENTAL
Intervention: Three drugs (cyclophosphamide, methotrexate, and prednisone) given to 49 patients
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Five drugs (cyclophosphamide, methotrexate, prednisone, vincristine, and 5-fluorouracil) given to 66 patients
Number of subjects: 115

Group type: COMPARATOR
Intervention: Both treatment groups (three drugs and five drugs)
Number of subjects: 115
Study: 31645293

Group type: EXPERIMENTAL
Intervention: Matriderm®
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Integra®
Number of subjects: 24
Study: 30998517

Group type: EXPERIMENTAL
Intervention: B. longum 1714™
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 28282530

Group type: EXPERIMENTAL
Intervention: COPCA (Coping with and Caring for infants with special needs)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Traditional infant physiotherapy (TIP)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: COPCA
Number of subjects: 40

Group type: COMPARATOR
Intervention: TIP
Number of subjects: 40
Study: 25380801

Group type: EXPERIMENTAL
Intervention: Fermented milk containing at least 6.5×10^9 cfu of Lactobacillus casei strain Shirota (LcS), one bottle/day for 6 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo, one bottle/day for 6 weeks
Number of subjects: 40
Study: 24094567

Group type: EXPERIMENTAL
Intervention: Threat group
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Mastery group
Number of subjects: 80
Study: 22079192

Group type: EXPERIMENTAL
Intervention: CSF IgG from 2 consecutive lumbar punctures
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Phage peptides
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Peptides recognized by OCBs
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Database search and alanine scan mutagenesis
Number of subjects: 5
Study: 19048384

Group type: EXPERIMENTAL
Intervention: Fascial sling
Number of subjects: 60

Group type: COMPARATOR
Intervention: TVT
Number of subjects: 60
Study: 16715289

Group type: EXPERIMENTAL
Intervention: Office hysteroscopy (Group II a)
Number of subjects: 520

Group type: EXPERIMENTAL
Intervention: Office hysteroscopy (Group II b)
Number of subjects: 520

Group type: COMPARATOR
Intervention: No office hysteroscopy (Group I)
Number of subjects: 520
Study: 15237585

Group type: EXPERIMENTAL
Intervention: Alternating scheme (3 cycles of 5‐fluorouracil and leucovorin followed by pelvic radiotherapy and 3 weeks after radiation therapy, another 3 cycles of chemotherapy)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Concomitant scheme (2 cycles of 5‐fluorouracil and leucovorin followed by concurrent radiochemotherapy and 3 weeks after ending, another 2 cycles of 5‐fluorouracil and leucovorin)
Number of subjects: 127
Study: 11413440

Group type: EXPERIMENTAL
Intervention: 360 degrees fusion (ALIF + transpedicular instrumentation + PLF)
Number of subjects: 48

Group type: COMPARATOR
Intervention: 270 degrees fusion (ALIF + transpedicular instrumentation without PLF)
Number of subjects: 48
Study: 9409498

Group type: EXPERIMENTAL
Intervention: Infiltration with 2% lignocaine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Infiltration with normal saline
Number of subjects: 0

Group type: COMPARATOR
Intervention: No infiltration
Number of subjects: 0
Study: 8359086

Group type: EXPERIMENTAL
Intervention: Octreotide (100 micrograms intravenously)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 3127220

Group type: EXPERIMENTAL
Intervention: Single dose nifedipine
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Sustained nifedipine therapy (three times daily for five days)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Sublingual nitroglycerin
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 29779821

Group type: EXPERIMENTAL
Intervention: Whey protein supplementation (WPS) with dietary counseling (DC)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Control group (CG) with dietary counseling (DC)
Number of subjects: 126
Study: 27210234

Group type: EXPERIMENTAL
Intervention: Fascial manipulation (FM) added to standard care
Number of subjects: 51
Study: 24417971

Group type: EXPERIMENTAL
Intervention: Pranayama RM training (6 weeks, 5 times/week)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 54
Study: 22742692

Group type: EXPERIMENTAL
Intervention: Life review writing intervention (Share Your Life Story workshop, 8 weeks, once weekly)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 45